Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming
Silencing of the somatic cell type-specific genes is a critical yet poorly understood step in reprogramming. To uncover pathways that maintain cell identity, we performed a reprogramming screen using inhibitors of chromatin factors. Here, we identify acetyl-lysine competitive inhibitors targeting th...
Autores principales: | Ebrahimi, A, Sevinç, K, Sevinç, G, Cribbs, A, Philpott, M, Uyulur, F, Morova, T, Dunford, J, Göklemez, S, Arı, Ş, Oppermann, U, Onder, T |
---|---|
Formato: | Journal article |
Publicado: |
Springer Nature
2019
|
Ejemplares similares
-
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
por: Andrew R Conery, et al.
Publicado: (2016-01-01) -
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
por: Andrew R Conery, et al.
Publicado: (2016-07-01) -
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
por: Hay, D, et al.
Publicado: (2014) -
Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
por: Popp, T, et al.
Publicado: (2016) -
CBP/p300 bromodomain: new promising epigenetic target
por: Xiang Qiuping, et al.
Publicado: (2022-01-01)